ofloxacin has been researched along with 3'-hydroxy-5'-(4-isobutylpiperazinyl)benzoxazinorifamycin in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (53.33) | 18.2507 |
| 2000's | 6 (40.00) | 29.6817 |
| 2010's | 1 (6.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bera, S; Mondal, D | 1 |
| Dekio, S; Hidaka, T; Kawahara, S; Saito, H; Sato, K; Tomioka, H | 1 |
| Akaki, T; Sato, K; Tomioka, H | 2 |
| Akaki, T; Kawahara, S; Sato, K; Shimizu, T; Tomioka, H | 1 |
| Maw, WW; Saito, H; Sato, K; Tomioka, H | 1 |
| Duncan, K | 1 |
| Sato, K; Tomioka, H | 1 |
| Akaki, T; Ogasawara, K; Sato, K; Tomioka, H | 1 |
| Akaki, T; Kajitani, H; Sato, K; Shishido, S; Tomioka, H | 1 |
| Dhople, AM | 1 |
| Akaki, T; Kawahara, S; Sato, K; Tomioka, H | 1 |
| Sano, C; Sano, K; Sato, K; Shimizu, T; Tomioka, H | 1 |
| Hammerschlag, MR; Kutlin, A; Reznik, T; Roblin, PM | 1 |
| Murphy, CK; Osburne, MS; Rothstein, DM | 1 |
3 review(s) available for ofloxacin and 3'-hydroxy-5'-(4-isobutylpiperazinyl)benzoxazinorifamycin
| Article | Year |
|---|---|
Insights of synthetic analogues of anti-leprosy agents.
Topics: Humans; Leprostatic Agents; Leprosy; Structure-Activity Relationship | 2019 |
The impact of genomics on the search for novel tuberculosis drugs.
Topics: Acetamides; Antitubercular Agents; Drug Design; Genome, Bacterial; Mycobacterium tuberculosis; Ofloxacin; Oxazoles; Rifamycins | 1998 |
[In vitro antimicrobial activities of quinolones, rifamycins and macrolides against Mycobacterium tuberculosis and M.avium complex: attempt to establish new assay methods which accurately reflect therapeutic effects of test agents in vivo].
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Antibiotics, Antitubercular; Cells, Cultured; Clarithromycin; Drug Resistance, Microbial; Humans; Microbial Sensitivity Tests; Mycobacterium avium Complex; Mycobacterium tuberculosis; Ofloxacin; Rifamycins | 1999 |
12 other study(ies) available for ofloxacin and 3'-hydroxy-5'-(4-isobutylpiperazinyl)benzoxazinorifamycin
| Article | Year |
|---|---|
Therapeutic effect of KRM-1648 with various antimicrobials against Mycobacterium avium complex infection in mice.
Topics: Animals; Antitubercular Agents; Clarithromycin; Clofazimine; Drug Synergism; Drug Therapy, Combination; Ethambutol; Fluoroquinolones; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Microbial Sensitivity Tests; Mycobacterium avium-intracellulare Infection; Ofloxacin; Quinolones; Rifamycins; Streptomycin | 1995 |
[Anti-Mycobacterium avium complex activities of KRM-1648, clarithromycin and levofloxacin in 7HSF medium at peak or average blood concentrations after their oral administration of clinical dosages].
Topics: Administration, Oral; Anti-Bacterial Agents; Anti-Infective Agents; Antibiotics, Antitubercular; Clarithromycin; Culture Media; Humans; Levofloxacin; Mycobacterium avium Complex; Ofloxacin; Rifamycins | 1997 |
[In vivo activities of benzoxazinorifamycin KRM-1648, clarithromycin, and levofloxacin, or combination of KRM-1648 with diclofenac sodium against Mycobacterium avium infection induced in mice].
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibiotics, Antitubercular; Clarithromycin; Diclofenac; Drug Therapy, Combination; Female; Levofloxacin; Mice; Mice, Inbred BALB C; Mycobacterium avium; Ofloxacin; Rifamycins; Tuberculosis | 1997 |
Studies on therapeutic activity of benzoxazinorifamycin KRM-1648 in combination with other antimicrobial agents and biological response modifiers interferon-gamma and granulocyte-macrophage colony-stimulating factor against M. leprae infection in athymic
Topics: Adoptive Transfer; Animals; Clofazimine; Dapsone; Drug Therapy, Combination; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Immunologic Factors; Interferon-gamma; Leprostatic Agents; Leprosy; Mice; Mice, Inbred BALB C; Mice, Nude; Ofloxacin; Rifamycins | 1997 |
Antimicrobial activities of benzoxazinorifamycin KRM-1648, clarithromycin and levofloxacin against intracellular Mycobacterium avium complex phagocytosed by murine peritoneal macrophages.
Topics: Animals; Anti-Bacterial Agents; Clarithromycin; Female; Levofloxacin; Lung; Macrophages, Peritoneal; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Mycobacterium avium; Ofloxacin; Phagocytosis; Rifamycins; Tuberculosis | 1998 |
[MICs and MBCs of levofloxacin, clarithromycin, and KRM-1648 for Mycobacterium tuberculosis and M. avium complex residing in MONO-MAC-6 human macrophage-like cell and A-549 human type II alveolar epithelial cell lines].
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Antibiotics, Antitubercular; Cells, Cultured; Clarithromycin; Humans; Levofloxacin; Macrophages; Microbial Sensitivity Tests; Mycobacterium avium Complex; Mycobacterium tuberculosis; Ofloxacin; Pulmonary Alveoli; Rifamycins | 1999 |
Comparative antimicrobial activities of the newly synthesized quinolone WQ-3034, levofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex.
Topics: 4-Quinolones; Aminopyridines; Anti-Infective Agents; Antitubercular Agents; Ciprofloxacin; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Mycobacterium avium Complex; Mycobacterium tuberculosis; Ofloxacin; Quinolones; Rifamycins | 2000 |
In vitro activity of KRM-1648, either singly or in combination with ofloxacin, against Mycobacterium ulcerans.
Topics: Anti-Infective Agents; Antibiotics, Antitubercular; Drug Interactions; Humans; Microbial Sensitivity Tests; Mycobacterium ulcerans; Ofloxacin; Rifamycins | 2001 |
Antimicrobial activities of levofloxacin, clarithromycin, and KRM-1648 against Mycobacterium tuberculosis and Mycobacterium avium complex replicating within Mono Mac 6 human macrophage and A-549 type II alveolar cell lines.
Topics: Anti-Bacterial Agents; Cell Line; Clarithromycin; Epithelial Cells; Humans; Levofloxacin; Macrophages; Microbial Sensitivity Tests; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Mycobacterium tuberculosis; Ofloxacin; Pulmonary Alveoli; Rifamycins; Tuberculosis | 2000 |
Intramacrophage passage of Mycobacterium tuberculosis and M. avium complex alters the drug susceptibilities of the organisms as determined by intracellular susceptibility testing using macrophages and type II alveolar epithelial cells.
Topics: Anti-Bacterial Agents; Antibiotics, Antitubercular; Cells, Cultured; Clarithromycin; Epithelial Cells; Humans; Levofloxacin; Macrophages; Microbial Sensitivity Tests; Mycobacterium avium Complex; Mycobacterium tuberculosis; Ofloxacin; Rifamycins | 2002 |
In vitro activities of rifamycin derivatives ABI-1648 (Rifalazil, KRM-1648), ABI-1657, and ABI-1131 against Chlamydia trachomatis and recent clinical isolates of Chlamydia pneumoniae.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Antibiotics, Antitubercular; Azithromycin; Chlamydia Infections; Chlamydia trachomatis; Chlamydophila pneumoniae; Humans; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Rifamycins | 2003 |
Enhanced activity of rifalazil in combination with levofloxacin, linezolid, or mupirocin against Staphylococcus aureus in vitro.
Topics: Acetamides; Anti-Bacterial Agents; Drug Resistance, Bacterial; Drug Therapy, Combination; Levofloxacin; Linezolid; Microbial Sensitivity Tests; Mupirocin; Ofloxacin; Oxazolidinones; Rifamycins; Staphylococcus aureus | 2006 |